We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Resistant to strain

5 August 2016 By Neil Unmack

The Danish pharma group’s shares fell more than 8 percent after it lowered profit and sales guidance and warned of lower prices in the key U.S. insulin market. Such pressures won’t abate. Still, in a growing market, Novo warrants a premium over peers. Just a less hefty one.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)